Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Peter Goss who wrote (5024)	5/9/1999 6:46:00 PM
From: spunky71	Read Replies (3) \| Respond to of 5736

Dear Peter, As I am a long term holder of CCSI, and suffered through the last 11 months of pain, and margin calls, I believe maybe I can shed some light on why people like myself are still involved with CCSI. I have no problems with shorts sellers, per se, as we all are here to make money. I do take offense to most of what happened to CCSI, but that is history, and the market is the judge and jury, and now we are somewhere in between. I know only what I read from the company in their SEC documents, and all the huffing and puffing by both sides is meaningless, as neither side seems to have a real grasp on timing of any nature. Even though I do not agree with you, at least you present your side in a reasonable fashion, and I respect that. I invest primarily in technology of all kinds, and have had decent success with medical technology, as that is my background and training. I have had the good fortune to see the TLc_BiliTest in a NICU in my area, and have attended two shows where the product was displayed, and the opportunity to test it myself. A deal to me is secondary, as it is my belief that this product is going to have a universal application for almost any birthing hospital anywhere. As, I am sure you know, these things do not happen overnight, but once they are accepted by a group of the leading hospitals, it will be fairly soon thereafter that they will wind up in hospitals, that might not have had a earlier interest. I assume that is why they are working on a deal. I know CCSI's sales force and their background, and these people are trained and professional, and seem to have left key places to join CCSI. That to me was the most important endorsement of the product. A successful device needs a dedicated and faithful sales force, just not detail people with their whole bag of products. I have read every document and paper I could find on Bilirubin, and numbers of tests done each year. I am not an analyst, but it is safe to say that there are over 13 mm tests in the US alone, and if indeed this product is what it looks like it might be, then that market could be increased dramatically for in- home and subsequent follow up visits at pediatrician offices. A little known fact, and I have not seen it anywhere is the blood related problems with standard heel sticks. In some areas the numbers of other diseases manifesting themselves is unnecessarily large. Also, a few hospitals have been hit with lawsuits for early release of infants that later developed severe and debilitating effects from severe jaundice. I have no idea what the estimates for CCSI are, or can be, I only know this is a product that has a very large market, that increases each year, and if they are successful with their roll out, then I would assume the numbers will follow along. I do know some of the long time shareholders, and I guess you can say we(they) are a loyal group, and after what we(they) have been through it is time for the market to determine what the company is worth, your ideas and mine differ, but that is what makes the world go round. As the acceptance grows with the NICU's then I believe the product will start to accelerate along a normal new medical device growth curve, and as I understand their pricing, it can become an annuity stream of income.